Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome - Related Studies

Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome

This study has been completed.

Study NCT00001145. Last updated on March 3, 2008. Information provided by National Institutes of Health Clinical Center (CC)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Immunoproliferative Disorder

2	Additional conditions recognized in this trial
		Hyper-IgM Immunodeficiency Syndrome
		Hyper-IgM Immunodeficiency Syndrome, Type 1
		Immunoproliferative Disorders
		Syndrome

3	More general conditions related to this trial
		Blood Protein Disorders
		Disease
		Dysgammaglobulinemia
		Genetic Diseases, Inborn
		Genetic Diseases, X-Linked
		Hematologic Diseases
		Immune System Diseases
		Immunologic Deficiency Syndromes
		Pathologic Processes

4	Interventions listed in this trial
		Bacteriophage
		rhuCD40L
		KLH

5	Sponsors listed in this trial
		National Institute of Allergy and Infectious Diseases (NIAID)